{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:30:50Z","timestamp":1781818250567,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016608","name":"Rainwater Charitable Foundation","doi-asserted-by":"publisher","award":["A130340"],"award-info":[{"award-number":["A130340"]}],"id":[{"id":"10.13039\/100016608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prior research identified profound sleep disruption in progressive supranuclear palsy (PSP). The hypothalamus and brainstem, areas that help regulate sleep\/wake patterns, are among the earliest affected brain regions in PSP disease progression. Comparing polysomnography and quantitative-neuropathology metrics, we identified relative sparing of wake-promoting nuclei in PSP compared to Alzheimer\u2019s disease, though PSP had more disrupted sleep. It led to the hypothesis that PSP patients have hyperinsomnia (or hyposomnia, little sleep) due to degeneration of sleep nuclei with a preservation of sleep neurons, causing a system unbalance. A higher neuronal count of wake-promoting nuclei was associated with greater nocturnal wake, regardless of disease. Specifically, orexinergic wake-promoting neurons in the lateral hypothalamus, previously described as the sleep-on\/off switch, are relatively spared in PSP. Thus, we hypothesized that an orexinergic antagonist may be more effective in treating sleep\/wake issues in PSP than other hypnotic medications. This study protocol was established to test the safety and efficacy of an orexinergic antagonist (suvorexant) targeting the wake-promoting system and contrasts it with a GABAergic receptor agonist (zolpidem) targeting sleep-promoting systems and placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a remote clinical trial, designed as a double-blind, cross-over, within-subject 6-week trial, with 3 one-week-long conditions, separated by 1-week washout periods. The order of the 3 regimens is randomized and counterbalanced: placebo (microcrystalline cellulose), 15\u00a0mg\/day suvorexant, 5\u00a0mg\/day zolpidem. Participants are recruited from doctor and study referrals, registries, and support groups. Once onboarded, the trial coordinator maintains communication with the participant\/caregiver throughout the 6\u00a0weeks. Assessments include neurological interviews, cognitive testing, and subjective questionnaire packets. Sleep and circadian rhythms are assessed through ambulatory EEG and actigraphy monitoring devices worn by the participant throughout the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The study design aims to reduce participant and caregiver burden, while improving accessibility to such a study. Administering a remote clinical trial for a rare disease, however, creates unique issues that would otherwise be absent from in-person studies. Particularly, a symptom rather than disease-modifying trial is challenging to recruit for when potential disease-modifying therapeutics are available. Needing to coordinate with non-associated medical offices to attain medical records or prescriptions can cause frustrations for the potential participant, medical office, and study team. In recruitment, onboarding, and trial maintenance, this study design relies on consistent communication to support participant enrollment and satisfaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP); NCT04014389. Registered on\u00a0June 2, 2019.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09382-9","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:36:33Z","timestamp":1767792993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Disturbed Sleep in Progressive Supranuclear Palsy: a randomized, remote, double-blinded, 6-week cross-over design study protocol comparing zolpidem, suvorexant, and placebo"],"prefix":"10.1186","volume":"27","author":[{"given":"Esther","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Yack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samirah","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Pandher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Prufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mayzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary H.","family":"Heuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Koestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawren","family":"Vandevrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea T.","family":"Grinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2282-1531","authenticated-orcid":false,"given":"Christine M.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Neylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"9382_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","volume":"8","author":"DR Williams","year":"2009","unstructured":"Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8:270\u20139.","journal-title":"Lancet Neurol"},{"key":"9382_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/s-0034-1381736","volume":"34","author":"LI Golbe","year":"2014","unstructured":"Golbe LI. Progressive supranuclear palsy. Semin Neurol. 2014;34:151\u20139.","journal-title":"Semin Neurol"},{"key":"9382_CR3","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/brainsci12091126","volume":"12","author":"Y Barer","year":"2022","unstructured":"Barer Y, Chodick G, Cohen R, Grabarnik-John M, Ye X, Zamudio J, et al. Epidemiology of progressive supranuclear palsy: real world data from the second largest health plan in Israel. Brain Sci. 2022;12:1126.","journal-title":"Brain Sci"},{"key":"9382_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archneur.1990.00530050077015","volume":"47","author":"J Grafman","year":"1990","unstructured":"Grafman J, Litvan I, Gomez C, Chase TN. Frontal lobe function in progressive supranuclear palsy. Arch Neurol. 1990;47:553\u20138.","journal-title":"Arch Neurol"},{"key":"9382_CR5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1212\/WNL.41.8.1257","volume":"41","author":"R Johnson","year":"1991","unstructured":"Johnson R, Litvan I, Grafman J. Progressive supranuclear palsy: altered sensory processing leads to degraded cognition. Neurology. 1991;41:1257\u20131257.","journal-title":"Neurology"},{"key":"9382_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","volume":"47","author":"I Litvan","year":"1996","unstructured":"Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1\u20139.","journal-title":"Neurology"},{"key":"9382_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40120-022-00420-1","volume":"12","author":"G Respondek","year":"2023","unstructured":"Respondek G, Breslow D, Amirghiasvand C, Ghosh B, Bergmans B, van Wyk L, et al. The lived experiences of people with progressive supranuclear palsy and their caregivers. Neurol Ther. 2023;12:229\u201347.","journal-title":"Neurol Ther"},{"key":"9382_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","volume":"10","author":"JC Steele","year":"1964","unstructured":"Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333\u201359.","journal-title":"Arch Neurol"},{"key":"9382_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mds.22946","volume":"25","author":"JD Rohrer","year":"2010","unstructured":"Rohrer JD, Paviour D, Bronstein AM, O\u2019Sullivan SS, Lees A, Warren JD. Progressive supranuclear palsy syndrome presenting as progressive nonfluent aphasia: a neuropsychological and neuroimaging analysis. Mov Disord. 2010;25:179\u201388.","journal-title":"Mov Disord"},{"key":"9382_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496\u2013503.","journal-title":"Neurology"},{"key":"9382_CR11","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/brain\/awm104","volume":"130","author":"DR Williams","year":"2007","unstructured":"Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson\u2019s syndrome. Brain. 2007;130:1566\u201376.","journal-title":"Brain"},{"key":"9382_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.04.014","volume":"73","author":"DG Coughlin","year":"2020","unstructured":"Coughlin DG, Litvan I. Progressive supranuclear palsy: advances in diagnosis and management. Parkinsonism Relat Disord. 2020;73:105\u201316.","journal-title":"Parkinsonism Relat Disord"},{"key":"9382_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer AL, Yu J-T, Golbe LI, Litvan I, Lang AE, H\u00f6glinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;16:552\u201363.","journal-title":"Lancet Neurol"},{"key":"9382_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/practneurol-2020-002794","volume":"21","author":"JB Rowe","year":"2021","unstructured":"Rowe JB, Holland N, Rittman T. Progressive supranuclear palsy: diagnosis and management. Pract Neurol. 2021;21:376\u201383.","journal-title":"Pract Neurol"},{"key":"9382_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1212185","author":"ML Dale","year":"2023","unstructured":"Dale ML, Silva-Batista C, de Almeida FO, Horak FB. Balance and gait in progressive supranuclear palsy: a narrative review of objective metrics and exercise interventions. Front Neurol. 2023. https:\/\/doi.org\/10.3389\/fneur.2023.1212185.","journal-title":"Front Neurol"},{"key":"9382_CR16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5603\/PJNNS.a2023.0044","volume":"57","author":"P Alster","year":"2023","unstructured":"Alster P, Madetko-Alster N, Migda A, Migda B, Kuty\u0142owski M, Kr\u00f3licki L, et al. Sleep disturbances in progressive supranuclear palsy syndrome (PSPS) and corticobasal syndrome (CBS). Neurol Neurochir Pol. 2023;57:229\u201334.","journal-title":"Neurol Neurochir Pol"},{"key":"9382_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jamaneurol.2022.0429","volume":"79","author":"JY Oh","year":"2022","unstructured":"Oh JY, Walsh CM, Ranasinghe K, et al. Subcortical neuronal correlates of sleep in neurodegenerative diseases. JAMA Neurol. 2022;79:498\u2013508.","journal-title":"JAMA Neurol"},{"key":"9382_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2019.01.020","volume":"398","author":"H Wilson","year":"2019","unstructured":"Wilson H, Niccolini F, Pellicano C, Politis M. Cortical thinning across Parkinson\u2019s disease stages and clinical correlates. J Neurol Sci. 2019;398:31\u20138.","journal-title":"J Neurol Sci"},{"key":"9382_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/cne.903530402","volume":"353","author":"CB Saper","year":"1995","unstructured":"Saper CB. The spinoparabrachial pathway: shedding new light on an old path. J Comp Neurol. 1995;353:477\u20139.","journal-title":"J Comp Neurol"},{"key":"9382_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1212\/WNL.49.4.999","volume":"49","author":"J Montplaisir","year":"1997","unstructured":"Montplaisir J, Petit D, D\u00e9cary A, Masson H, B\u00e9dard MA, Panisset M, et al. Sleep and quantitative EEG in patients with progressive supranuclear palsy. Neurology. 1997;49:999\u20131003.","journal-title":"Neurology"},{"key":"9382_CR21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/sleep\/28.4.418","volume":"28","author":"I Arnulf","year":"2005","unstructured":"Arnulf I, Merino-Andreu M, Bloch F, Konofal E, Vidailhet M, Cochen V, et al. REM sleep behavior disorder and REM sleep without atonia in patients with progressive supranuclear palsy. Sleep. 2005;28:349\u201354.","journal-title":"Sleep"},{"key":"9382_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsx154","volume":"40","author":"CM Walsh","year":"2017","unstructured":"Walsh CM, Ruoff L, Walker K, et al. Sleepless night and day, the plight of progressive supranuclear palsy. Sleep. 2017;40:zsx154.","journal-title":"Sleep"},{"key":"9382_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101541","volume":"60","author":"CH Lew","year":"2021","unstructured":"Lew CH, Petersen C, Neylan TC, Grinberg LT. Tau-driven degeneration of sleep- and wake-regulating neurons in Alzheimer\u2019s disease. Sleep Med Rev. 2021;60:101541.","journal-title":"Sleep Med Rev"},{"key":"9382_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/jnen\/nlx113","volume":"77","author":"RA Eser","year":"2018","unstructured":"Eser RA, Ehrenberg AJ, Petersen C, et al. Selective vulnerability of brainstem nuclei in distinct tauopathies: a postmortem study. J Neuropathol Exp Neurol. 2018;77:149\u201361.","journal-title":"J Neuropathol Exp Neurol"},{"key":"9382_CR25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jalz.2019.06.3916","volume":"15","author":"J Oh","year":"2019","unstructured":"Oh J, Eser RA, Ehrenberg AJ, et al. Profound degeneration of wake-promoting neurons in Alzheimer\u2019s disease. Alzheimers Dement. 2019;15:1253\u201363.","journal-title":"Alzheimers Dement"},{"key":"9382_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/nature04284","volume":"437","author":"CB Saper","year":"2005","unstructured":"Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437:1257\u201363.","journal-title":"Nature"},{"key":"9382_CR27","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","volume":"79","author":"WJ Herring","year":"2012","unstructured":"Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265\u201374.","journal-title":"Neurology"},{"key":"9382_CR28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.5664\/jcsm.6116","volume":"12","author":"WJ Herring","year":"2016","unstructured":"Herring WJ, Connor KM, Snyder E, et al. Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials. J Clin Sleep Med. 2016;12:1215\u201325.","journal-title":"J Clin Sleep Med"},{"key":"9382_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","volume":"13","author":"D Michelson","year":"2014","unstructured":"Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:461\u201371.","journal-title":"Lancet Neurol"},{"key":"9382_CR30","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.clinthera.2016.09.010","volume":"38","author":"JL Schroeck","year":"2016","unstructured":"Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Ther. 2016;38:2340\u201372.","journal-title":"Clin Ther"},{"key":"9382_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJM199908123410721","volume":"341","author":"A Daniele","year":"1999","unstructured":"Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med. 1999;341:543\u20134.","journal-title":"N Engl J Med"},{"key":"9382_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1046\/j.1468-1331.2002.0354g.x","volume":"9","author":"BJ Mayr","year":"2002","unstructured":"Mayr BJ, Bonelli RM, Niederwieser G, K\u00f6ltringer P, Reisecker F. Zolpidem in progressive supranuclear palsy. Eur J Neurol. 2002;9:184\u20135.","journal-title":"Eur J Neurol"},{"key":"9382_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jocn.2009.05.038","volume":"17","author":"C Cotter","year":"2010","unstructured":"Cotter C, Armytage T, Crimmins D. The use of zolpidem in the treatment of progressive supranuclear palsy. J Clin Neurosci. 2010;17:385\u20136.","journal-title":"J Clin Neurosci"},{"key":"9382_CR34","volume":"2013","author":"SK Dash","year":"2013","unstructured":"Dash SK. Zolpidem in progressive supranuclear palsy. Case Rep Neurol Med. 2013;2013:e250865.","journal-title":"Case Rep Neurol Med"},{"key":"9382_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/107064","author":"AY Chang","year":"2014","unstructured":"Chang AY, Weirich E. Trial of zolpidem, eszopiclone, and other GABA agonists in a patient with progressive supranuclear palsy. Case Rep Med. 2014. https:\/\/doi.org\/10.1155\/2014\/107064.","journal-title":"Case Rep Med"},{"key":"9382_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol. 2014;13:676\u201385.","journal-title":"Lancet Neurol"},{"key":"9382_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.parkreldis.2016.04.014","volume":"28","author":"J Bang","year":"2016","unstructured":"Bang J, Lobach IV, Lang AE, et al. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord. 2016;28:41\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"9382_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.sleep.2016.05.002","volume":"22","author":"CM Walsh","year":"2016","unstructured":"Walsh CM, Ruoff L, Varbel J, Walker K, Grinberg LT, Boxer AL, et al. Rest-activity rhythm disruption in progressive supranucl","journal-title":"Sleep Med"},{"key":"9382_CR39","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606\u201313.","journal-title":"J Gen Intern Med"},{"key":"9382_CR40","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092\u20137.","journal-title":"Arch Intern Med"},{"key":"9382_CR41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.sleep.2010.12.009","volume":"12","author":"BF Boeve","year":"2011","unstructured":"Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo sleep questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011;12:445\u201353.","journal-title":"Sleep Med"},{"key":"9382_CR42","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540\u20135.","journal-title":"Sleep"},{"key":"9382_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/sleep\/34.5.601","volume":"34","author":"CM Morin","year":"2011","unstructured":"Morin CM, Belleville G, B\u00e9langer L, Ivers H. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34:601\u20138.","journal-title":"Sleep"},{"key":"9382_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.parkreldis.2020.08.021","volume":"79","author":"AE Lang","year":"2020","unstructured":"Lang AE, Stebbins GT, Wang P, et al. The cortical basal ganglia functional scale (CBFS): development and preliminary validation. Parkinsonism Relat Disord. 2020;79:121\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"9382_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jns.2006.05.030","volume":"248","author":"A Schrag","year":"2006","unstructured":"Schrag A. Quality of life and depression in Parkinson\u2019s disease. J Neurol Sci. 2006;248:151\u20137.","journal-title":"J Neurol Sci"},{"key":"9382_CR46","doi-asserted-by":"publisher","unstructured":"Hoddes E, Dement WC, Zarcone V. Stanford Sleepiness Scale. 2015. https:\/\/doi.org\/10.1037\/t07116-000.","DOI":"10.1037\/t07116-000"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09382-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09382-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09382-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:02:51Z","timestamp":1770285771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-025-09382-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9382"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09382-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4421625\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been reviewed and ethically approved through the Western IRB (WIRB). WIRB is the IRB of reliance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The model consent will be available upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"Thomas C. Neylan, MD is the principal investigator and does not have any other competing interests. UCSF is the only current study site on this protocol. Advanced Brain Monitoring, Inc. loaned the study team Sleep Profiler devices for use in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"105"}}